Barclays
ELOX

Barclays’s Eloxx Pharmaceuticals ELOX Stock Holding History

Barclays’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167 Buy
+12
New +$153 ﹤0.01% 5137

Other funds holding ELOX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SGM
Seven Grand Managers Bronxville, New York $2.48B AUM 65.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's ELOX Position: Q2 2026 in Review

Barclays opened a new position in Eloxx Pharmaceuticals (ELOX) in Q2 2026: 12 shares worth $167. The stake represents ﹤0.01% of the portfolio and ranks #5137 among its holdings.

22 funds tracked by Wall St. Rank hold ELOX as of Q2 2026.

  • Barclays held 12 shares of Eloxx Pharmaceuticals worth $167 as of Q2 2026.
  • Eloxx Pharmaceuticals was a new Barclays position in Q2 2026.
  • Eloxx Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5137 holding.
  • 22 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.